Format

Send to

Choose Destination
J Scleroderma Relat Disord. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926. Epub 2018 Jul 18.

An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Author information

1
Division of Rheumatology, Jewish General Hospital, Montreal, Canada.
2
Faculty of Rheumatology, University of Toledo Medical Center, Toledo, OH, USA.
3
Columbia University College of Physicians and Surgeons, New York, New York.
4
Department of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
5
Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; University College London, London, United Kingdom.
6
Insitute of Immunity and Transplantation, University College London, London, United Kingdom.
7
Arthritis and Autoimmunity Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
8
Division of Rheumatology, St. Vincent's Hospital, Melbourne, Australia.
9
Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany.
10
Department of Rheumatology, University of Utah, UT, USA.
11
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
12
Department of Rheumatology, Toronto Western Hospital, Toronto, Canada.
13
Division of Rheumatology, University of Michigan, MI, USA.
14
Rheumatology Department, Johns Hopkins Hospital, M.D., USA.
15
Department of Medicine, University of Pennsylvania, PA, USA.
16
Department of Rheumatology, Hosfra Northwell School of Medicine.
17
Department of Rheumatology, Royal National Hospital for Rheumatic Diseases University of Bath.
18
Rheumatology Unit, University Hospital of Cagliari.

Abstract

The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis (SSc). The SCTC has established 11 working groups (WGs) to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the SCTC may join any one or more of these groups. Some of the WGs have only recently started their work, some are nearing completion of their mandated tasks and others are in the midst of their projects. All these projects, which are described in this paper, will help to improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, "To measure is to know. If you cannot measure it you cannot improve it." The SCTC is dedicated to improving the lives of patients with SSc and it is our hope that the contributions of the WGs will be one important step in this process.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center